ARTICLE | Company News
EMA to review axitinib for RCC
June 2, 2011 12:08 AM UTC
EMA accepted for review an MAA from Pfizer Inc. (NYSE:PFE) for axitinib to treat advanced renal cell carcinoma after failure of prior systemic treatment. Axitinib is an inhibitor of VEGF receptors 1, ...